The proposal to make drug test reports public in India through a digital platform has been shelved in its current form. The proposal was discussed during the 70th meeting of the Drugs Consultative Committee (DCC) in September 2026, but it did not receive consensus.
The proposed system was intended to improve transparency and accountability in drug quality surveillance. However, concerns were raised regarding the verification, authenticity and regulatory oversight of drug test information before making it publicly available.
Quick Summary
The Centre has shelved its proposal to create a digital platform for publicly disclosing drug test reports. The proposal was discussed at the 70th DCC meeting but did not achieve consensus. Future disclosure may require stronger verification, authenticity checks and a broader regulatory framework for reliable drug-quality information.
What Was the Proposal About?
The proposal considered creating a digital platform for public disclosure of drug test reports related to batches tested during routine quality surveillance.
The main objective was to increase transparency regarding the quality of medicines and improve accountability when drug batches are examined through regulatory testing.
However, the proposal did not receive consensus in its current form.
According to the DCC discussion, simply uploading documents supplied by manufacturers would not necessarily establish their authenticity or confirm the quality status of a particular drug batch. Verification and appropriate regulatory oversight were therefore considered important.
Why Was the Plan Shelved?
One of the major concerns was verification of drug test reports.
The DCC discussion indicated that a public digital disclosure mechanism would need to be part of a broader and verifiable regulatory system. Simply publishing test documents online would not be sufficient without mechanisms to establish authenticity and provide suitable regulatory oversight.
Key Concerns
A reliable public disclosure system would need to address:
- Authenticity of drug test reports
- Verification of test results
- Correct association of results with the relevant drug batch
- Regulatory action following quality failures
- Accuracy and completeness of publicly available information
These requirements were highlighted in the discussion around creating a broader, verifiable regulatory framework.
What Is the Drugs Consultative Committee (DCC)?
The Drugs Consultative Committee (DCC) is a statutory advisory committee associated with India’s drug regulatory framework.
The official CDSCO website lists the 70th DCC meeting as being held on 18 September 2026, with its minutes subsequently published.
The committee discusses regulatory matters related to drugs and provides recommendations concerning implementation and regulatory mechanisms.
What Happens to Drug Quality Alerts Currently?
India already publishes information about drug batches identified as Not of Standard Quality (NSQ) or spurious through its monthly quality review system.
The NSQ dashboard can provide information such as:
| Information | Details |
|---|---|
| Batch Number | Identifies the affected drug batch |
| Manufacturer | Name of the manufacturer |
| Test Results | Results associated with the tested sample |
However, publicly available information does not necessarily show how far a flagged sample exceeded prescribed parameters or the regulatory action taken after the failure.
Why Is Verification of Drug Test Reports Important?
Drug-quality information can affect pharmaceutical companies, regulators, healthcare professionals and patients. Therefore, a public database needs mechanisms to ensure that the information is accurate and reliable.
A reliable system should ensure that:
- Test reports are authentic.
- Information is correctly linked to the relevant batch.
- Results are properly verified.
- Regulatory action is accurately recorded.
- Public information is not misleading or incomplete.
The DCC discussion specifically pointed toward the need for a broader and verifiable regulatory system before introducing such a digital disclosure mechanism.
Industry Concerns Over Public Disclosure
The proposed transparency measures have also been discussed in relation to their potential impact on pharmaceutical companies.
According to the report covered in the original article, some industry stakeholders had raised concerns regarding an earlier proposal related to public disclosure of risk-based inspections and possible unintended consequences for the pharmaceutical industry.
This illustrates the regulatory challenge of balancing:
- Public transparency
- Drug-quality information
- Verification of information
- Regulatory oversight
- Potential consequences for pharmaceutical companies
How Are Drug Quality Problems Reported Currently?
Under the existing system, drug batches identified as NSQ or spurious are disclosed through the monthly quality review process.
The NSQ dashboard can include details such as the:
- Manufacturer
- Batch number
- Test results
The proposed digital platform would have provided more direct public access to drug test reports. However, the proposal has not received consensus in its current form.
Global Comparison: US FDA
The original report also refers to the US FDA as an example of a regulatory agency providing online access to certain inspection information.
The US system can provide information such as:
| Information | Example |
|---|---|
| Company | Name of the company |
| Inspection Date | Date of inspection |
| Location | Inspection location |
| Classification | Final inspection classification |
Examples of inspection classifications include NAI (No Action Indicated), VAI (Voluntary Action Indicated) and OAI (Official Action Indicated).
However, the report notes that this database does not provide detailed findings of those inspections.
What Could Happen Next?
Shelving the proposal in its current form does not necessarily mean that wider digital transparency will never be considered.
The DCC discussion indicates that any future digital disclosure mechanism would likely need to be incorporated into a broader and verifiable regulatory framework.
Such a framework would need to address:
- Authenticity of information
- Verification of test results
- Regulatory oversight
- Accuracy of publicly disclosed information
before wider public disclosure is introduced.
Current Status of Drug Test Reports in India
| Point | Current Status |
|---|---|
| Public digital platform for drug test reports | Shelved in current form |
| Committee involved | Drugs Consultative Committee |
| DCC Meeting | 70th DCC Meeting |
| Meeting Date | 18 September 2026 |
| Main Objective | Greater transparency and accountability |
| Major Concern | Verification and authenticity |
| Current NSQ Information | Available through monthly quality review |
| Future Digital Disclosure | May require a broader verifiable regulatory system |
Why Should Pharmacy Candidates Know About This Update?
This regulatory development is relevant to B.Pharm, M.Pharm, Pharm.D and other pharmacy students and professionals because drug-quality regulation is an important part of the pharmaceutical sector.
Pharmacy candidates preparing for regulatory and government examinations can benefit from understanding topics such as:
- Not of Standard Quality (NSQ) drugs
- Spurious drugs
- Drug testing laboratories
- Quality surveillance
- CDSCO
- Drugs Consultative Committee
- Regulatory compliance
- Drug quality alerts
These concepts are relevant to pharmacy education as well as preparation for regulatory and government pharmacy examinations.
Frequently Asked Questions
What is the latest update on making drug test reports public in India?
The Centre has shelved the proposal for a digital platform to publicly disclose drug test reports in its current form because the proposal did not achieve consensus.
Which committee discussed the proposal?
The proposal was discussed during the 70th meeting of the Drugs Consultative Committee (DCC) held on 18 September 2026.
Why was the proposal not approved in its current form?
A major concern was that simply uploading documents would not establish their authenticity or ensure reliable verification without effective regulatory oversight.
Are drug quality test results currently available to the public?
Information about drug batches identified as NSQ or spurious is currently disclosed through the monthly quality review system and NSQ dashboard.
What does NSQ mean in pharmaceuticals?
NSQ means Not of Standard Quality. It refers to a drug batch that does not meet the applicable prescribed quality standards.
Will drug test reports become public in the future?
The current proposal has been shelved, but future consideration may be possible as part of a broader and verifiable regulatory system.
What is the role of CDSCO?
The Central Drugs Standard Control Organisation (CDSCO) is India’s central drug regulatory authority and plays a key role in the regulation and quality oversight of drugs and related products.
Why is drug quality surveillance important for pharmacy students?
Drug quality surveillance helps pharmacy students understand concepts related to NSQ drugs, spurious drugs, drug testing, regulatory compliance and pharmaceutical quality oversight.
Important Official Sources
For verification and further reading, refer to:
- 70th DCC Meeting – Official CDSCO Page
- 70th DCC Meeting Minutes – CDSCO PDF
- ETPharma Report: Centre Shelves Plan to Make Drug Test Reports Public
These sources are listed in the original article.
Conclusion
The proposal to make drug test reports public in India through a dedicated digital platform has been shelved in its current form following the discussion at the 70th DCC meeting.
The key issue highlighted in the discussion was the need for reliable verification, authenticity and regulatory oversight before drug-quality information is made widely available to the public.
For now, information concerning NSQ and spurious drug batches continues to be communicated through the existing quality-review system. Any future move toward wider digital disclosure is likely to depend on developing a system capable of providing accurate, authentic and verifiable drug-quality information.
Recommended Products
